Weight Loss Surgery vs Ozempic: Which Is Better?
Surgery or weight loss medication — which has the stronger long-term impact on heart health?
GLP-1 receptor agonist medications, such as semaglutide and tirzepatide, have changed the way obesity is treated. For many people, they reduce hunger, support weight loss, and improve important health markers.
But a recent real-world comparison found that metabolic and bariatric surgery may provide greater long-term cardiovascular benefit, especially when looking at lifetime risk rather than short-term risk alone.
Both medication and surgery can help — but the size and durability of weight loss may matter most for long-term heart health.
What did the study compare?
The study compared adults with obesity who received either metabolic and bariatric surgery or GLP-1 receptor agonist therapy.
The researchers looked at changes after one year, focusing on cardiovascular risk, body weight, blood pressure, and cholesterol levels.
The two treatment groups were:
- Metabolic and bariatric surgery, including sleeve gastrectomy, gastric bypass, and duodenal switch procedures.
- GLP-1 receptor agonist therapy, including medications such as semaglutide and tirzepatide.
The goal was not simply to ask, “Which treatment causes weight loss?” The more important question was: which treatment improves long-term cardiometabolic risk?
Why cardiovascular risk matters
Obesity is closely linked with several conditions that increase the risk of cardiovascular disease, including type 2 diabetes, high blood pressure, abnormal cholesterol, and chronic inflammation.
Cardiovascular disease remains one of the most serious long-term risks for people living with obesity. This is why treatment should not only focus on the number on the scale.
Effective obesity treatment should aim to improve:
- Body weight and body composition.
- Blood pressure and cardiovascular strain.
- Cholesterol levels, including LDL and HDL cholesterol.
- Blood sugar control and diabetes risk.
- Long-term heart and vascular health.
The key finding: surgery had a greater lifetime risk reduction
At one year, both groups showed improvement in estimated 10-year cardiovascular risk. This means both GLP-1RA therapy and surgery appeared to improve short-term cardiometabolic health.
However, the major difference was seen in estimated lifetime cardiovascular risk. Bariatric surgery was associated with a much larger reduction in lifetime ASCVD risk compared with GLP-1RA therapy.
In simple terms:
- Short-term cardiovascular risk improved with both approaches.
- Lifetime cardiovascular risk improved more after surgery.
- Surgery produced greater weight loss at one year.
- Surgery also produced stronger improvements in cholesterol markers.
This suggests that deeper and more durable weight loss may create stronger long-term heart health benefits.
How much weight loss was seen?
One of the clearest differences between the two treatment groups was the amount of total body weight loss achieved after one year.
In the study, metabolic and bariatric surgery was associated with substantially greater total body weight loss compared with GLP-1 receptor agonist therapy.
At one year:
- Bariatric surgery: around 27.8% total body weight loss.
- GLP-1RA therapy: around 11.1% total body weight loss.
This does not mean medication is ineffective. GLP-1RA therapy can be highly effective for many people. But when comparing the two approaches directly, surgery produced a larger average weight loss in this cohort.
Why lifetime risk is important
Ten-year cardiovascular risk can be helpful, especially for older adults. But it is heavily influenced by age, sex, and other factors that do not change quickly.
Lifetime cardiovascular risk can better reflect the benefit of improving weight, cholesterol, blood pressure, and metabolic health earlier in life.
This matters because:
- A person may not see a dramatic change in short-term risk after only one year.
- Long-term risk may still improve meaningfully if weight, cholesterol, and metabolic health improve.
- Younger patients may benefit from earlier intervention because there is more time for risk reduction to matter.
- Obesity treatment should be considered as a long-term health strategy, not just a short-term weight loss plan.
What happened to cholesterol and blood pressure?
The study found that blood pressure improved modestly in both groups, with no major difference between surgery and GLP-1RA therapy.
Cholesterol changes were more favourable after surgery. Compared with GLP-1RA therapy, surgery was associated with larger reductions in total cholesterol and LDL cholesterol, as well as greater increases in HDL cholesterol.
Why this matters:
- LDL cholesterol is often called “bad cholesterol” because higher levels are linked with plaque buildup in arteries.
- HDL cholesterol is often called “good cholesterol” because it helps transport cholesterol away from the arteries.
- Improving cholesterol can reduce long-term cardiovascular risk.
- Weight loss alone is not the only goal; improving metabolic health is just as important.
Does this mean surgery is better than medication?
Not necessarily for every person. The study suggests that surgery may provide greater reductions in lifetime cardiovascular risk, but GLP-1RA medications still play an important role.
Medication may be suitable for people who are not ready for surgery, are not surgical candidates, have a lower BMI, or want a less invasive treatment option. Surgery may be more appropriate when more substantial and durable weight loss is needed.
GLP-1RA medication may be useful if:
- You need help reducing appetite and hunger.
- You have weight-related health issues but are not ready for surgery.
- You are looking for a non-surgical treatment option.
- You understand that ongoing use may be needed for maintenance.
- You can tolerate the medication and manage the cost, access, and side effects.
Surgery may be worth considering if:
- You have a higher BMI and need more substantial weight loss.
- You have type 2 diabetes, high blood pressure, sleep apnea, or abnormal cholesterol.
- You have lost weight before but regained it repeatedly.
- Medication worked while you were taking it, but weight returned after stopping.
- Your long-term cardiovascular risk or quality of life is becoming a serious concern.
The treatments can also work together
One of the most important messages from modern obesity care is that treatment does not need to be either medication or surgery.
For some people, GLP-1RA medications may be used before surgery to reduce risk, after surgery to support further weight loss, or alongside a long-term medical plan.
The right treatment pathway depends on your BMI, health conditions, weight history, appetite, medication response, and long-term goals.
The best option is the one that matches the seriousness of the problem and gives you the strongest chance of maintaining the result.
What should patients take from this?
This study adds to a growing body of evidence that obesity treatment should be judged by long-term health outcomes, not just short-term weight loss.
GLP-1RA medications are a major advance and can be life-changing for many people. But for people with higher BMI, repeated weight regain, or significant cardiometabolic risk, surgery may offer stronger long-term benefits.
The main takeaways:
- Both medication and surgery can improve cardiovascular risk.
- Surgery was linked with greater lifetime cardiovascular risk reduction.
- Surgery produced greater average weight loss at one year.
- Surgery showed stronger improvements in cholesterol levels.
- Medication remains an important option, especially for those not ready or suitable for surgery.
- The right decision should be individual, medical, and long term.
There is no shame in needing a stronger option
If weight loss medication has helped but has not been enough, or if weight returns when medication stops, that does not mean you have failed.
It may mean your body needs a stronger or more durable intervention. Obesity is a chronic medical condition, and the treatment should match the biology, health risks, and long-term pattern of the condition.
Surgery is not the easy way out. Medication is not a shortcut. Both are medical tools that can help people regain control of their health.
The goal is not just to lose weight. The goal is to protect your health for the long term.
Learn more
Source: Ghusn W, Vierkant RA, Jawhar N, et al.
Metabolic and Bariatric Surgery vs Glucagon-like peptide-1 Receptor Agonist Therapy: A Head-to-Head Comparison in Improvement of Cardiometabolic Risk Profiles.
Annals of Surgery. Published ahead of print. DOI: 10.1097/SLA.0000000000007064.